51214 Deucravacitinib efficacy in palmoplantar and fingernail psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA) in the phase 3 POETYK PSO-1 and PSO-2 trials
Elewski, Boni, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Cather, Jennifer
Published in Journal of the American Academy of Dermatology (01.09.2024)
Published in Journal of the American Academy of Dermatology (01.09.2024)
Get full text
Journal Article
P096 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials
Kearney, Niamh, Pink, Andrew, Hoyt, Kim, Kisa, Renata M, Banerjee, Subhashis, Rogers, Alexandra, Mullan, Jill, Warren, Richard B
Published in British journal of dermatology (1951) (28.06.2024)
Published in British journal of dermatology (1951) (28.06.2024)
Get full text
Journal Article
51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data
Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.
Published in Journal of the American Academy of Dermatology (01.09.2024)
Published in Journal of the American Academy of Dermatology (01.09.2024)
Get full text
Journal Article
51091 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials
Gold, Linda Stein, Banerjee, Subhashis, Colombo, Matthew J., Kisa, Renata M., Berger, Victoria, Hoyt, Kim, Soung, Jennifer, Torres, Tiago, Bhatia, Neal, Glick, Brad P., Kaufmann, Mark D.
Published in Journal of the American Academy of Dermatology (01.09.2024)
Published in Journal of the American Academy of Dermatology (01.09.2024)
Get full text
Journal Article
51101 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline static Physician Global Assessment (sPGA) in two phase 3 trials
Sobell, Jeffrey M., Elewski, Boni, Seo, Seong Jun, Banerjee, Subhashis, Balagula, Eugene, Scharnitz, Thomas, Hoyt, Kim, Yamauchi, Paul, Bettencourt, Miriam, Cameron, Michael C., Lebwohl, Mark
Published in Journal of the American Academy of Dermatology (01.09.2024)
Published in Journal of the American Academy of Dermatology (01.09.2024)
Get full text
Journal Article
Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data
Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.
Published in Skin (Milwood, N.Y.) (23.07.2024)
Published in Skin (Milwood, N.Y.) (23.07.2024)
Get full text
Journal Article
Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program
Lebwohl, Mark, Egeberg, Alexander, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Strober, Bruce
Published in Skin (Milwood, N.Y.) (13.03.2023)
Published in Skin (Milwood, N.Y.) (13.03.2023)
Get full text
Journal Article
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials
Lebwohl, Mark, Strober, Bruce, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Mehta, Nehal N.
Published in Skin (Milwood, N.Y.) (13.03.2023)
Published in Skin (Milwood, N.Y.) (13.03.2023)
Get full text
Journal Article
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Lebwohl, Mark, Strober, Bruce, Scharnitz, Thomas, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Martin, George
Published in Skin (Milwood, N.Y.) (13.11.2023)
Published in Skin (Milwood, N.Y.) (13.11.2023)
Get full text
Journal Article
Tear Film Metric Derived from Twyman-Green Interferometry of Tear Films
Hofmann, Greg, Coles-Brennon, Chantal, Hoyt, Kim, Cheng, Xu, Buch, John, Cannon, Jessica, Fadli, Zohra
Published in Contact lens & anterior eye (01.12.2019)
Published in Contact lens & anterior eye (01.12.2019)
Get full text
Journal Article
Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Banerjee, Subhashis, Colombo, Matthew J., Scharnitz, Thomas, Hoyt, Kim, Thaci, Diamant, Blauvelt, Andrew
Published in Skin (Milwood, N.Y.) (23.07.2024)
Published in Skin (Milwood, N.Y.) (23.07.2024)
Get full text
Journal Article
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)
Armstrong, April W., Lebwohl, Mark, Bagel, Jerry, Schlesinger, Todd, Banerjee, Subhashis, Kisa, Renata M., Scharnitz, Thomas, Hoyt, Kim, Strober, Bruce
Published in Skin (Milwood, N.Y.) (13.03.2023)
Published in Skin (Milwood, N.Y.) (13.03.2023)
Get full text
Journal Article
Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Blauvelt, Andrew, Korman, Neil J., Merola, Joseph F., Gooderham, Melinda, Balagula, Eugene, Vanlandingham, Rebecca, Treitel, Michelle, Wittstock, Keith, Hoyt, Kim, Banerjee, Subhashis, Desai, Seemal R.
Published in Skin (Milwood, N.Y.) (18.03.2024)
Published in Skin (Milwood, N.Y.) (18.03.2024)
Get full text
Journal Article
Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Thaçi, Diamant, Lebwohl, Mark, Warren, Richard B., Kircik, Leon, Banerjee, Subhashis, Napoli, Andrew, Kisa, Renata M., Linaberry, Misti, Hoyt, Kim, Blauvelt, Andrew
Published in Skin (Milwood, N.Y.) (13.11.2023)
Published in Skin (Milwood, N.Y.) (13.11.2023)
Get full text
Journal Article
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)
Sobell, Jeffrey M., Elewski, Boni, Banerjee, Subhashis, Balagula, Eugene, Scharnitz, Thomas, Berger, Victoria, Hoyt, Kim, Yamauchi, Paul, Bettencourt, Miriam, Cameron, Michael C., Lebwohl, Mark
Published in Skin (Milwood, N.Y.) (13.11.2023)
Published in Skin (Milwood, N.Y.) (13.11.2023)
Get full text
Journal Article
Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Strober, Bruce, Imafuku, Shinichi, Paul, Carle, Gooderham, Melinda, Spelman, Lynda, Seo, Seong Jun, Passeron, Thierry, Hoyt, Kim, Colombo, Matthew J., Banerjee, Subhashis, Augustin, Matthias, Stein Gold, Linda, Alexis, Andrew F., Thaci, Diamant, Lebwohl, Mark, Issa, Naiem T., Cameron, Michael C.
Published in Skin (Milwood, N.Y.) (23.07.2024)
Published in Skin (Milwood, N.Y.) (23.07.2024)
Get full text
Journal Article
Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program
Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Banerjee, Subhashis, Kisa, Renata M., Vritzali, Eleni, Colombo, Matthew J., Scharnitz, Thomas, Hoyt, Kim, Thaçi, Diamant, Blauvelt, Andrew
Published in Skin (Milwood, N.Y.) (18.03.2024)
Published in Skin (Milwood, N.Y.) (18.03.2024)
Get full text
Journal Article
Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Kisa, Renata M., Berger, Victoria, Vritzali, Eleni, Hoyt, Kim, Colombo, Matthew J., Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew
Published in Skin (Milwood, N.Y.) (18.03.2024)
Published in Skin (Milwood, N.Y.) (18.03.2024)
Get full text
Journal Article
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
Blauvelt, Andrew, Rich, Phoebe, Sofen, Howard, Lambert, Jo, Merola, Joseph F, Lebwohl, Mark, Scharnitz, Thomas, Hoyt, Kim, Kisa, Renata M, Banerjee, Subhashis
Published in Skin (Milwood, N.Y.) (16.11.2022)
Published in Skin (Milwood, N.Y.) (16.11.2022)
Get full text
Journal Article